|
|
|
|
|
| Bilar,Juliana Miguel; Carvalho-Filho,Roberto José; Mota,Carolina Frade Magalhães Girardin Pimentel; Fucuta,Patricia da Silva; Ferraz,Maria Lucia Cardoso Gomes. |
| Approximately 170 million people are infected with hepatitis C, and the sustained virological response rate to treatment with pegylated interferon and ribavirin is 30-50%. In an attempt to improve the chances of cure, boceprevir is being added to therapy, but it is associated with an increased incidence of adverse events. We herein report a case of acute pancreatitis developed during treatment with pegylated interferon, ribavirin and boceprevir. Boceprevir was the most likely cause of drug-associated pancreatitis after the most common causes were ruled out, since this adverse event had not occurred when the patient had previously been exposed to pegylated interferon and ribavirin and there was no recurrence of the episode of pancreatitis when these two... |
| Tipo: Info:eu-repo/semantics/report |
Palavras-chave: Hepatitis C; Protease inhibitor; Side effect. |
| Ano: 2014 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702014000400454 |
| |
|
|
| Pessoa,Luciana Santos; Vidal,Luãnna Liebscher; Costa,Emmerson C.B. da; Abreu,Celina Monteiro; Cunha,Rodrigo Delvecchio da; Valadão,Ana Luiza Chaves; Santos,André Felipe dos; Tanuri,Amilcar. |
| Abstract Approximately 185 million people worldwide are chronically infected with hepatitis C virus (HCV). The first-wave of approved NS3 protease inhibitors (PIs) were Telaprevir and Boceprevir, which are currently discontinued. Simeprevir is a second-wave PI incorporated into the Brazilian hepatitis C treatment protocol. Drug resistance plays a key role in patients' treatment regimen. Here, we developed a simple phenotypic assay to evaluate the impact of resistance mutations in HCV NS3 protease to PIs, using a protein expression vector containing wild type NS3 protease domain and NS4A co-factor. We analyzed the impact of five resistance mutations (T54A, V36M, V158I, V170I and T54S+V170I) against Telaprevir, Boceprevir and Simeprevir. Protein... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Protease inhibitor; Phenotypic test; Hepatitis C virus; HCV NS3 protease; Resistance mutation. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572016000300358 |
| |
|
|
| Melo,Nadja Rodrigues de; Vilela,Maria Marluce Santos; Jorge Junior,Jacks; Kamei,Katsuhiko; Miyaji,Makoto; Fukushima,Kazutaka; Nishimura,Kazuko; Groeneveld,Philip; Kelly,Steven L.; Taguchi,Hideaki. |
| Declining incidence of oropharyngeal candidosis and opportunistic infections over recent years can be attributed to the use of highly active anti-retroviral therapy (HAART). Infection with C. albicans generally involves adherence and colonization of superficial tissues. During this process, budding yeasts are able to transform to hyphae and penetrate into the deep tissue. Using the biocell tracer system, C. albicans hyphal growth was dynamically observed at the cellular level. Ritonavir was effective in the inhibition of hyphal growth with growth rate of 0.8 mum/min. This study showed the in vitro effect of HIV anti-retroviral drug on the growth rate of the C. albicans hyphae. |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Candida; Hyphal; Protease inhibitor. |
| Ano: 2006 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822006000300006 |
| |
|
| |
|
|
| Miotto,N.; Mendes,L.C.; Zanaga,L.P.; Goncales,E.S.L.; Lazarini,M.S.K.; Pedro,M.N.; Goncales Jr.,F.L.; Stucchi,R.S.B.; Vigani,A.G.. |
| The aim of this study was to determine risk factors for adverse events (AE)-related treatment discontinuation and severe anemia among patients with chronic hepatitis C virus (HCV) genotype 1 infection, treated with first-generation protease inhibitor (PI)-based therapy. We included all patients who initiated treatment with PI-based therapy at a Brazilian university hospital between November 2013 and December 2014. We prospectively collected data from medical records using standardized questionnaires and used Epi Info 6.0 for analysis. Severe anemia was defined as hemoglobin ≤8.5 mg/dL. We included 203 patients: 132 treated with telaprevir (TVR) and 71 treated with boceprevir (BOC). AE-related treatment discontinuation rate was 19.2% and anemia was the main... |
| Tipo: Info:eu-repo/semantics/article |
Palavras-chave: Hepatitis C treatment; Protease inhibitor; Anemia; Adverse events; Treatment interruption. |
| Ano: 2016 |
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2016000700702 |
| |
|
| |
|
| |
|
|
|
